Nrx pharmaceuticals builds on its intellectual property foundation for neuropsychiatric conditions - adds new u.s. patent to portfolio

Company receives notice of the issuance of a u.s. patent covering the lead formulation, nrx-101, a glycine site nmda antagonist in clinical trials to treat bipolar depression with acute and subacute suicidality; this new patent represents a third patent family, that now totals 48 issued patents worldwide with 42 additional pending patent applications. patent covers the use of nrx-101 to treat patients suffering from depression, including bipolar depression or major depression (mdd) with or without suicidality and strengthens the company's intellectual property position until at least 2033; upon approval of nrx-101, this newly granted patent is expected to be "listable" in the u.s. food and drug administration (fda) orange book.
NRXP Ratings Summary
NRXP Quant Ranking